AstraZeneca Reports Positive Results of 2 Lung Cancer Trials
September 11 2017 - 2:51AM
Dow Jones News
By Ian Walker
Pharmaceutical giant AstraZeneca PLC (AZN.LN) Monday reported
positive results from two trials for lung cancer treatments.
It said a Phase III Pacific trial of Imfinzi improved
progression-free survival by more than 11 months compared with
standard of care. AstraZeneca added that the trial continues to
evaluate the other primary endpoint, overall survival.
The company also said a Phase III Flaura trial of Tagrisso
reduced the risk of progression or death by more than half, with
consistent benefit across all subgroups, including patients with
and without brain metastases.
Tagrisso also showed median progression-free survival of 18.9
months, compared with 10.2 months for the current standard of care,
AstraZeneca said.
Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
September 11, 2017 02:36 ET (06:36 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
